Home Featured Page 21

Featured

Latest

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions

AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal

PS 25 Morning Show – Day Three

When it Comes to Psychedelic Access, It’s the Messenger, Not the...

Australia’s Largest Private Health Insurer Commits $10M to Fund MDMA Therapy...

Ibogaine and the Future of Healing: Trevor Millar & Jonathan Dickinson...

Psychedelic legend “the Acid King” William Leonard Pickard Announced as Keynote...

Accredited Entheogenic Seminary: Inside the Congregation for Sacred Practices with Paul...

Does Cannabis Research Deserve As Much Funding As Ibogaine Research?

Pα+ Psychedelic Bulletin #201: Dispatches from Prague and London; Texas Becomes...

EDITOR PICKS

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions

AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal

PS 25 Morning Show – Day Three

PS 25 Morning Show – Day Two

When it Comes to Psychedelic Access, It’s the Messenger, Not the...

PS 25 Morning Show – Day One

Australia’s Largest Private Health Insurer Commits $10M to Fund MDMA Therapy...

Ibogaine and the Future of Healing: Trevor Millar & Jonathan Dickinson...

Psychedelic legend “the Acid King” William Leonard Pickard Announced as Keynote...

Accredited Entheogenic Seminary: Inside the Congregation for Sacred Practices with Paul...

Does Cannabis Research Deserve As Much Funding As Ibogaine Research?

Pα+ Psychedelic Bulletin #201: Dispatches from Prague and London; Texas Becomes...

EDITOR PICKS

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY